New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
13:25 EDTOMEDOncoMed pullback a buying opportunity, says Piper Jaffray
Piper Jaffray believes the pullback in shares of OncoMed provides an attractive entry point into the name ahead of additional clinical data readouts in June. The reiterates an Overweight rating on the stock with a $48 price target.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2015
05:48 EDTOMEDMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use